Natalya Gromyko

Natalya Gromyko is an experienced professional in pharmaceutical commercialization and strategy development. Currently serving as Director of New Product Commercialization at Apellis Pharmaceuticals since July 2025, Gromyko previously held the role of independent consultant where expertise included commercialization strategy and data analytics. At EMD Serono, Gromyko was the New Product Planning Director for the Fertility Franchise and co-led strategy development for the Neurology and Immunology portfolio. Prior experience at Biogen involved leadership in competitive intelligence for SPINRAZA and insights for TECFIDERA's re-launch. Gromyko started a career at Vertex Pharmaceuticals as Associate Director, impacting market access for KALYDECO. Academic credentials include an MBA in Strategy and Finance from The Wharton School and a Bachelor of Science from Millersville University of Pennsylvania.